The Synergistic Treatment of Heart and Kidney Disease
Abstract
Background: The incidence and prevalence of both cardiac and renal disease in Germany are steadily rising. Heart disease is the most common cause of death, especially among people with chronic kidney disease. Impaired kidney function increases the risk of cardiovascular events, and vice versa.
Methods: This narrative review is based on pertinent publications retrieved by a literature search up to the year 2025, with particular attention to the guidelines of the Association of the Scientific Medical Societies in Germany (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF) and the European Society of Cardiology (ESC). Supplementary searches were conducted on individual aspects of the epidemiology, diagnosis, and treatment of heart and kidney disease.
Results: The heart and the kidneys are closely pathophysiologically linked. Both can be damaged by shared vascular risk factors, including diabetes mellitus, arterial hypertension, and chronic inflammation. These shared mechanisms give rise to a continuum of diseases. Multiple RCTs have shown in recent years that the morbidity and mortality of patients with heart and kidney diseases can be significantly lowered by treatment not only with ACE inhibitors, but also with sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP1-RA), and nonsteroidal mineralocorticoid receptor antagonists (nsMRA). Absolute risk reductions in the range of 1.8% to 6.7% have been…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.